XPC and malignant colon neoplasm: Strikingly, the only exception was GG-NER, as impairment of XPC or DDB2 had no impact on the sensitivity of DLD-1 colon cancer cells to oxaliplatin, while it did cause hypersensitivity to cisplatin.